Stockscreener 앱 받기
134.93
0.60%
-0.82
시간 외 거래:
136.26
1.33
+0.99%
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Axsome Therapeutics’ Earnings Call Highlights Growth and Challenges - TipRanks
Biologics Market Surges Toward $680B as FDA Accelerates Approval Pathways - The Globe and Mail
Morgan Stanley Maintains Axsome Therapeutics (AXSM) Overweight Recommendation - Nasdaq
(AXSM) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
AXSM: Morgan Stanley Raises Price Target and Maintains Overweigh - GuruFocus
AXSM: RBC Capital Raises Price Target and Maintains Outperform R - GuruFocus
AXSM: Wells Fargo Maintains Overweight Rating, Lowers Price Targ - GuruFocus
Is Axsome Therapeutics Set for More Gains After 54% Rally and Clinical Pipeline News? - Yahoo Finance
Axsome Therapeutics (NASDAQ:AXSM) Shares Gap Down After Earnings Miss - MarketBeat
AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales - sharewise.com
Axsome anticipates expanded market access for SYMBRAVO and AUVELITY while advancing late-stage pipeline - MSN
Axsome Therapeutics (NASDAQ:AXSM) Posts Earnings Results, Misses Expectations By $0.12 EPS - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2025 Earnings Call Transcript - Insider Monkey
RBC Raises Price Target on Axsome Therapeutics to $198 From $189, Keeps Outperform Rating - MarketScreener
Axsome Therapeutics (AXSM): Net Margin Stays Negative as Growth Expectations Drive Up Valuation Debate - Yahoo Finance
Will Axsome Therapeutics Inc. stock go up soonWeekly Stock Recap & High Accuracy Trade Alerts - newser.com
Needham Reiterates Axsome Therapeutics (AXSM) Buy Recommendation - Nasdaq
Axsome: Q3 Earnings Snapshot - New Haven Register
Published on: 2025-11-04 04:14:34 - newser.com
How Axsome Therapeutics Inc. (19X) stock moves in volatile trading sessionsQuarterly Profit Report & Risk Managed Investment Strategies - newser.com
Can machine learning forecast Axsome Therapeutics Inc. recoveryQuarterly Growth Report & Accurate Intraday Trading Signals - newser.com
How Axsome Therapeutics Inc. stock compares to industry benchmarksWeekly Risk Summary & Proven Capital Preservation Tips - newser.com
Axsome Therapeutics Inc. stock trend forecast2025 Trading Volume Trends & Long-Term Growth Stock Strategies - newser.com
Decoding Axsome Therapeutics Inc (AXSM): A Strategic SWOT Insigh - GuruFocus
Axsome Therapeutics Reports Strong Q3 2025 Growth - TipRanks
Has Axsome Therapeutics Inc. formed a bullish divergenceTrade Risk Assessment & Precise Entry and Exit Recommendations - newser.com
Axsome Therapeutics Inc (AXSM) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
Axsome Therapeutics Q3 2025 slides: Strong revenue growth amid pipeline expansion - Investing.com
Axsome Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Transcript : Axsome Therapeutics, Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Axsome Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Axsome Therapeutics Q3 2025 reveals revenue beat, stock dips - Investing.com
Is Axsome Therapeutics Inc. forming a reversal pattern2025 Market Outlook & Reliable Breakout Forecasts - newser.com
Axsome Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Axsome Therapeutics Saw Sales Jump But Losses Remain - Finimize
Market reaction to Axsome Therapeutics Inc.’s recent newsWeekly Investment Recap & Fast Gain Stock Trading Tips - newser.com
Axsome Therapeutics Q3 Net Loss Narrows, Revenue Rises - MarketScreener
Axsome Q3 2025 Financial Results: Revenue Beats, Loss WidensNews and Statistics - IndexBox
Axsome Therapeutics Reports 63% Revenue Growth in Q3 2025 - TipRanks
Earnings Flash (AXSM) Axsome Therapeutics Posts Q3 Net Loss $0.94 a Share, vs. FactSet Est of $0.82 Loss - MarketScreener
Earnings Flash (AXSM) Axsome Therapeutics, Inc. Reports Q3 Revenue $171.0M, vs. FactSet Est of $163.0M - MarketScreener
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Axsome Therapeutics Inc. stock momentum explainedJuly 2025 Snapshot & Free High Accuracy Swing Entry Alerts - newser.com
Axsome Therapeutics Q3 net product revenue jumps 63% - MarketScreener
Axsome Therapeutics Inc. recovery potential after sell offJuly 2025 Opening Moves & Reliable Price Action Trade Plans - newser.com
Will Axsome Therapeutics Inc. stock sustain high P E ratios2025 Growth vs Value & Daily Stock Trend Reports - newser.com
Axsome Therapeutics Inc. stock volume spike explained2025 Dividend Review & Verified Entry Point Signals - newser.com
Historical volatility pattern of Axsome Therapeutics Inc. visualized2025 Key Lessons & Daily Technical Forecast Reports - newser.com
How Axsome Therapeutics Inc. (19X) stock reacts to Fed tighteningJuly 2025 Analyst Calls & Free Fast Gain Swing Trade Alerts - newser.com
How rising interest rates impact Axsome Therapeutics Inc. stock2025 Sector Review & Community Shared Stock Ideas - newser.com
1.45%
0.86%
자본화:
|
볼륨(24시간):